← Back to home

Evaluation of the efficacy and safety of zeprumetostat in relapsed/refractory large granular lymphocyte leukemia (T-LGLL)

Clinical trials for Evaluation of the efficacy and safety of zeprumetostat in relapsed/refractory large granular lymphocyte leukemia (T-LGLL) explained in plain language.

Never miss a new study

Get alerted when new Evaluation of the efficacy and safety of zeprumetostat in relapsed/refractory large granular lymphocyte leukemia (T-LGLL) trials appear

Sign up with your email to follow new studies for Evaluation of the efficacy and safety of zeprumetostat in relapsed/refractory large granular lymphocyte leukemia (T-LGLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Experimental drug targets Hard-to-Treat leukemia in small early trial

Disease control Not yet recruiting

This early study tests an experimental drug called zeprumetostat in people with a rare type of leukemia (T-cell large granular lymphocyte leukemia) that has not responded to or has come back after other treatments. Ten participants take the drug twice daily for two 28-day cycles.…

Matched conditions: EVALUATION OF THE EFFICACY AND SAFETY OF ZEPRUMETOSTAT IN RELAPSED/REFRACTORY LARGE GRANULAR LYMPHOCYTE LEUKEMIA (T-LGLL)

Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control

Last updated Sep 21, 2026 20:00 UTC

Evaluation of the efficacy and safety of zeprumetostat in relapsed/refractory large granular lymphocyte leukemia (T-LGLL)

Get alerted when new Evaluation of the efficacy and safety of zeprumetostat in relapsed/refractory large granular lymphocyte leukemia (T-LGLL) trials appear

Experimental drug targets Hard-to-Treat leukemia in small early trial